NEW YORK (GenomeWeb News) – The German biotech company Kinaxo Biotechnologies, a spinout of the Max Planck Institute, and Bayer Vital announced today that they have formed a collaboration to identify novel phosphoproteomics biomarkers for predicting cancer treatment outcomes.

The researchers plan to use Kinaxo's quantitative phosphoproteomics technology, PhosphoScout, to find and quantify phosphorylation sites as part of a clinical trial conducted by Bayer Vital on the use of oral anti-cancer drug sorafenib (Nexavar) in acute myeloid leukemia.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.